Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
05 Juin 2023 - 12:06PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of
Foreign Private Issuer
Pursuant to Rule 13a-16 or
15d-16
of the Securities Exchange Act of 1934
For the month of June, 2023
Commission File Number: 001-36619
Affimed N.V.
Im
Neuenheimer Feld 582,
69120 Heidelberg,
Germany
(Address of
principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
☒ Form
20-F ☐ Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
AFFIMED N.V.
On June 3, 2023, Affimed N.V. (Nasdaq: AFMD) (Affimed, or the Company) issued a press release titled
Affimed Presents AFM24 Monotherapy Data in Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology and Provides Strategic Update on AFM24 Development Plan
announcing the presentation at the American Society of Clinical Oncology Annual Meeting of safety and efficacy data from the EGFR mutant NSCLC expansion cohort of its ongoing Phase 1/2 study investigating innate cell engager AFM24 as monotherapy.
The data included 15 evaluable patients and showed encouraging early signs of clinical activity including confirmed partial responses and durable stable disease. EGFR mutant NSCLC is a very aggressive and resistant tumor type in which most classical
NSCLC treatments achieve limited to no clinical activity, especially in more advanced patients. Affimeds innate cell engager AFM24 aims to reactivate the innate and consequently the adaptive immune system to recognize and destroy EGFR mutant
tumors.
At the planned interim analysis, 15 patients with EGFR mutant NSCLC and a median of 2 prior lines of therapy had been treated
with a median of 11 doses of AFM24. As of the cut-off date, the data showed clinical activity and signals of anti-tumor activity in 7 out of 15 heavily pre-treated
patients, including two confirmed partial responses and five patients with stable disease (SD) resulting in an objective response rate of 13% and a disease control rate of 47%. All patients with stable disease were progression free for at least 3.5
months, with one patient exhibiting ongoing SD for more than 8 months. A reduction in tumor burden was observed in five of 13 patients (38%) with available baseline and subsequent tumor assessments based on RECIST criteria. All patients showed a
well-managed safety profile with the majority exhibiting mild-to-moderate treatment-related adverse events in-line with previous
findings, highlighting the well-managed safety profile that makes AFM24 a candidate for combination approaches. One Grade 5 (pneumonitis) adverse event was reported in a patient with progressive disease and multiple comorbidities; however, since
relation to AFM24 could not be ruled out it is deemed treatment related. Although the formal continuation criteria for the cohort were not met, these data provide proof of concept that targeting NK cells can induce remission in patients with
especially hard-to-treat solid tumors.
INCORPORATION BY
REFERENCE
Exhibit 99.1 to this Report on Form 6-K shall not be deemed filed for purposes of Section 18 of
the Securities Exchange Act of 1934 (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
AFFIMED N.V. |
|
|
|
|
Date: June 4, 2023 |
|
|
|
By: |
|
/s/ Adi Hoess |
|
|
|
|
Name: Adi Hoess |
|
|
|
|
Title: Chief Executive Officer |
|
|
|
|
|
|
|
|
By: |
|
/s/ Angus Smith |
|
|
|
|
Name: Angus Smith |
|
|
|
|
Title: Chief Financial Officer |
Affimed NV (NASDAQ:AFMD)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Affimed NV (NASDAQ:AFMD)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024